Diseases & Longevity · File 30

Chronic kidney disease. The silent epidemic where real mortality is cardiovascular.

CKD affects approximately 850 million people worldwide — more than diabetes, more than combined cancer. It's asymptomatic until advanced stages. Most relevant: most CKD patients die from cardiovascular cause before reaching dialysis. SGLT2i and finerenone transformed the paradigm. Longevity medicine operates on the modifiable cardiorenal-metabolic cluster.

Why CKD is cardiovascular disease in addition to renal

The silent CKD is one of longevity's worst enemies — it doesn't hurt, doesn't give symptoms, and is detected late. But its real burden is not dialysis (which a minority reaches): it's the cardiovascular risk acceleration. CV mortality in CKD patients exceeds general population's many times — the mechanism is endothelial dysfunction, vascular calcification, anemia, inflammaging, and uremic dyslipidemia. Most die from the heart before reaching terminal kidney.

Modern screening uses cystatin C (more sensitive than creatinine alone, particularly in patients with sarcopenia or low muscle mass), calculated eGFR, and microalbuminuria. KDIGO 2024 updated classification and management. SGLT2i (DAPA-CKD, EMPA-KIDNEY) and finerenone (FIDELIO-DKD, FIGARO-DKD) demonstrated reduction of renal and cardiovascular events — transforming the paradigm. Longevity medicine operates on early screening and modifiable cardiorenal cluster.

Silent CKD is the antechamber of cardiovascular mortality. Screening it with cystatin C and microalbuminuria years before the renal symptom is real longevity medicine.
More than diabetes and cancer

The global weight, in numbers

Data come from GBD, KDIGO, ISN, and transformative trials (DAPA-CKD, EMPA-KIDNEY, FIDELIO-DKD). They confirm magnitude and opportunity.

  • Global burden

    850M · Lancet 2020

    CKD affects approximately 850 million people globally — more than diabetes and cancer combined. Systematic underdiagnosis: many patients only detected in advanced stages.
    — Bikbov et al., Lancet 2020

  • CV > terminal mortality

    Causa principal

    Most CKD patients die from cardiovascular cause before reaching terminal renal disease. That reorients the entire clinical conversation — it's not just "preserving the kidney", it's "preserving the heart with the kidney".
    — Go et al., NEJM 2004

  • SGLT2i reduces renal and CV events

    DAPA-CKD, EMPA-KIDNEY

    DAPA-CKD (Heerspink 2020 NEJM) and EMPA-KIDNEY (2023 NEJM): SGLT2i reduce major renal and cardiovascular events in CKD patients with or without diabetes. Changed therapeutic paradigm.
    — Heerspink NEJM 2020; EMPA-KIDNEY NEJM 2023

  • Finerenone in T2D+CKD

    FIDELIO-DKD, FIGARO-DKD

    Finerenone — non-steroidal mineralocorticoid receptor antagonist — demonstrated reduction of renal and cardiovascular events in T2D and CKD patients in FIDELIO-DKD (Bakris 2020 NEJM) and FIGARO-DKD (Pitt 2021 NEJM).
    — Bakris NEJM 2020; Pitt NEJM 2021

Chap. 03 · Cardiorenal-metabolic

The cardiorenal-metabolic cluster and longevity

CKD coexists with cardiometabolic cluster — T2D, HTN, dyslipidemia, central obesity, MASLD. Integrated cluster management is CV and renal prevention simultaneously.

  • Type 2 diabetes + CKD

    DKD · 40% pacientes

    Approximately 40% of T2D patients develop diabetic kidney disease (DKD). Glycemic control, lipid profile (ApoB), SGLT2i, and finerenone are interventions with solid effect in this cluster.
    — KDIGO 2024 Diabetes Guideline

  • Anemia and inflammaging

    Eje renal-hematológico

    CKD patients develop anemia (erythropoietin deficiency, functional iron deficiency) and systemic inflammaging — both amplify CV mortality and sarcopenia. Hematologic axis management is part of cluster.
    — KDIGO Anemia Guideline 2012

  • Renal osteodystrophy

    CKD-MBD

    CKD produces mineral and bone disorder (CKD-MBD) — secondary hyperparathyroidism, hyperphosphatemia, vascular calcification, fracture risk. Monitoring with calcium, phosphorus, PTH, and vitamin D, and specific management when indicated.
    — KDIGO CKD-MBD Guideline 2017

  • Sarcopenia and nutrition

    Caquexia renal

    Advanced CKD is associated with significant sarcopenia and renal cachexia. Individualized nutritional management (controlled protein in advanced, sufficient in early), strength exercise, and monitoring are indispensable. Nephrology coordination.
    — ISRNM 2013

What we don't offer — and what we do

Wellness Care does not perform dialysis or renal transplant. Vascular access preparation, hemodialysis, peritoneal dialysis, transplant, and management of advanced CKD (stages 4-5) are the nephrologist's and hospital's responsibility. What we do: early screening with cystatin C and microalbuminuria, reading CKD as cardiorenal-metabolic cluster, integrated systemic comorbidity management, and coordination with nephrology and cardiology.

We evaluate patients with: poorly controlled HTN, T2D, cardiometabolic cluster, detected microalbuminuria, borderline-decreased eGFR without clear etiology, family history of CKD, already-diagnosed CKD under nephrology management wanting to optimize systemic cardiovascular view. Evaluation integrates advanced biomarkers (cystatin C, ApoB, Lp(a), hsCRP), mineral-bone profile, body composition, mental health, and 14 Lancet Commission factors.

Silent CKD is the antechamber of cardiovascular mortality. Detecting it years before with cystatin C + microalbuminuria + addressing the cluster changes real trajectory.
How we measure it

How CKD is evaluated
at Wellness Care

Advanced screening + cardiorenal-metabolic cluster + systemic comorbidities (anemia, mineral-bone, sarcopenia) + coordination with nephrology and cardiology. That integration changes real outcomes.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications — Lancet 2020 global burden, DAPA-CKD, EMPA-KIDNEY, FIDELIO/FIGARO.

«La ERC afecta a 850 millones de personas globalmente — más que diabetes y cáncer combinados. Su subdiagnóstico sistemático es uno de los problemas centrales de salud pública del siglo XXI.»
Lancet · 2020
Bikbov et al., Lancet 2020
Carga global ERC
«Dapagliflozina redujo eventos renales y cardiovasculares mayores en pacientes con ERC con o sin diabetes — transformando el paradigma terapéutico.»
NEJM · 2020
Heerspink et al., NEJM 2020
DAPA-CKD
«Finerenona redujo eventos renales y cardiovasculares en pacientes con DM2 y ERC en FIDELIO-DKD y FIGARO-DKD.»
NEJM · 2020-2021
Bakris/Pitt et al., NEJM
FIDELIO/FIGARO

Frequently asked questions about chronic kidney disease

The most recurrent questions about CKD — screening, cystatin C, SGLT2i, finerenone, and why longevity medicine integrates it as cluster.

01

Why cystatin C and not just creatinine?

Because creatinine depends strongly on muscle mass.

Patients with "falsely normal" creatinine despite decreased renal function:

· Sarcopenia
· Low muscle mass
· Advanced age
· Cachexia

Cystatin C:

· Produced by all nucleated cells
· Doesn't depend on muscle mass
· More sensitive marker of early damage

KDIGO 2024 recommends using both in combined calculation (eGFR-cystatin-creatinine) to improve precision.

02

What is microalbuminuria and why does it matter?

It's the small but sustained albumin loss in urine:

· 30-300 mg/g creatinine in urinary albumin/creatinine ratio (ACR)

It's early marker of endothelial renal damage, BEFORE eGFR falls.

It's also an independent predictor of cardiovascular events.

Annual microalbuminuria screening in patients with:

· DM
· HTN
· Cardiometabolic cluster

Is modern standard. Its presence changes management:

· SGLT2i
· Finerenone
· ACEi/ARB

03

How did SGLT2i and finerenone change the paradigm?

For decades, CKD management was limited to:

· ACEi/ARB
· HTN control
· Glycemic control

With inexorable progression to dialysis in many patients.

SGLT2i transformed:

· DAPA-CKD (Heerspink 2020 NEJM)
· EMPA-KIDNEY (2023 NEJM)

Demonstrated reducing major renal events AND CV mortality in CKD patients with or without diabetes.

Finerenone in T2D+CKD:

· FIDELIO-DKD (Bakris 2020 NEJM)
· FIGARO-DKD (Pitt 2021 NEJM)

Both are now pillars in management. Decision and prescription by nephrology / endocrinology.

04

When should I consult?

A structured assessment is worthwhile if:

· Poorly controlled HTN
· T2D
· Cardiometabolic cluster
· Detected microalbuminuria
· Borderline-decreased eGFR without clear etiology
· Family history of CKD
· Already diagnosed CKD under nephrology management wanting to optimize systemic cardiovascular view
· Follow-up for DKD or associated CKD

The assessment complements nephrology / cardiology — does not replace them.

The silent antechamber of the heart

Silent CKD is the antechamber of cardiovascular mortality. Detecting it years before and addressing the cardiorenal cluster is real longevity medicine.

Screen with cystatin C + microalbuminuria, address cardiorenal-metabolic cluster, integrate SGLT2i and finerenone when indicated under nephrology management — that integration changes real mortality.

HTN, T2D, or suspected renal damage?

Book a comprehensive renal-cardiovascular assessment

We evaluate advanced renal profile (cystatin C, eGFR, microalbuminuria), cardiovascular profile (ApoB, Lp(a), hsCRP, ABPM), metabolic profile, amplified cardiometabolic cluster, and systemic comorbidities. Does not replace nephrology / cardiology — complements them with the longevity view.

Book renal-CV assessment